House Ped. Exclusivity Generic Approval Provision Would Save $67 Mil. – CBO
Executive Summary
A provision in the House pediatric exclusivity legislation to approve generic applications despite lacking the innovators' pediatric labeling would reduce federal spending by $67 mil. over 2002-2006
You may also be interested in...
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
Pediatric Labeling Would Not Block Generic Approval - House Exclusivity Bill
A generic drug would not have to include pediatric information in labeling in order to be approved under the pediatric exclusivity reauthorization bill passed by the House Commerce Committee.